|
Paciucci, P A; Ryder, J S; Mandell, J P et al. (2000) Interleukin-2 plus chemotherapy for patients with metastatic melanoma. Melanoma Res 10:291-5
|
|
Puolakkainen, P; Twardzik, D; Ranchalis, J et al. (1995) Increase of plasma transforming growth factor beta (TGF beta) during immunotherapy with IL-2. Cancer Invest 13:583-9
|
|
Silverman, L R; Deligdisch, L; Mandeli, J et al. (1994) Chemotherapy for angiosarcoma of the breast: case report of 30-year survival and analysis of the literature. Cancer Invest 12:145-55
|
|
Bhardwaj, S; Holland, J F; Norton, L (1993) An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest 11:6-9
|
|
Paciucci, P A; Bekesi, J G; Ryder, J S et al. (1991) Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Am J Clin Oncol 14:341-8
|
|
Head, J F; Chahinian, A P; Greengard, O (1991) Enzymic composition and growth rate of human pleural mesothelioma transplants in nude mice. Cancer Biochem Biophys 12:127-36
|
|
Crown, J; Lipzstein, R; Cohen, S et al. (1991) Chemotherapy of metastatic Merkel cell cancer. Cancer Invest 9:129-32
|
|
Oleksowicz, L; Paciucci, P A; Zuckerman, D et al. (1991) Alterations of platelet function induced by interleukin-2. J Immunother (1991) 10:363-70
|
|
Bruckner, H W; Cohen, C; Mandeli, J et al. (1991) Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience. Cancer Treat Rev 18 Suppl A:57-65
|
|
Yagi, M J; Bekesi, J G (1990) Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia. Cancer Chemother Pharmacol 26:215-20
|
Showing the most recent 10 out of 55 publications
